Cargando…

Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases

Exposure to sunlight and contact with atmospheric oxygen makes the eye particularly susceptible to oxidative stress, which can potentially produce cellular damage. In physiological conditions, there are several antioxidant defense mechanisms within the eye. Glutathione (GSH) is the most important an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebastián-Morelló, María, Alambiaga-Caravaca, Adrián M., Calatayud-Pascual, María Aracely, Rodilla, Vicent, Balaguer-Fernández, Cristina, Miranda, María, López-Castellano, Alicia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558315/
https://www.ncbi.nlm.nih.gov/pubmed/32927681
http://dx.doi.org/10.3390/pharmaceutics12090861
_version_ 1783594614020636672
author Sebastián-Morelló, María
Alambiaga-Caravaca, Adrián M.
Calatayud-Pascual, María Aracely
Rodilla, Vicent
Balaguer-Fernández, Cristina
Miranda, María
López-Castellano, Alicia
author_facet Sebastián-Morelló, María
Alambiaga-Caravaca, Adrián M.
Calatayud-Pascual, María Aracely
Rodilla, Vicent
Balaguer-Fernández, Cristina
Miranda, María
López-Castellano, Alicia
author_sort Sebastián-Morelló, María
collection PubMed
description Exposure to sunlight and contact with atmospheric oxygen makes the eye particularly susceptible to oxidative stress, which can potentially produce cellular damage. In physiological conditions, there are several antioxidant defense mechanisms within the eye. Glutathione (GSH) is the most important antioxidant in the eye; GSH deficit has been linked to several ocular pathologies. The aim of this study was to explore the potential for newly developed formulations allowing controlled delivery of antioxidants such as GSH and vitamin C (Vit C) directly to the eye. We have investigated the stability of antioxidants in aqueous solution and assessed ex-vivo the diffusion of GSH through two ocular membranes, namely cornea and sclera, either in solution or included in a semisolid insert. We have also carried out the hen’s egg-chlorioallantoic membrane test (HET-CAM) to evaluate the ocular irritancy of the different antioxidant solutions. Our results showed that GSH is stable for up to 30 days at 4 °C in darkness and it is not an irritant to the eye. The diffusion studies revealed that the manufactured formulation, a semisolid insert containing GSH, could deliver this tripeptide directly to the eye in a sustained manner.
format Online
Article
Text
id pubmed-7558315
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75583152020-10-22 Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases Sebastián-Morelló, María Alambiaga-Caravaca, Adrián M. Calatayud-Pascual, María Aracely Rodilla, Vicent Balaguer-Fernández, Cristina Miranda, María López-Castellano, Alicia Pharmaceutics Article Exposure to sunlight and contact with atmospheric oxygen makes the eye particularly susceptible to oxidative stress, which can potentially produce cellular damage. In physiological conditions, there are several antioxidant defense mechanisms within the eye. Glutathione (GSH) is the most important antioxidant in the eye; GSH deficit has been linked to several ocular pathologies. The aim of this study was to explore the potential for newly developed formulations allowing controlled delivery of antioxidants such as GSH and vitamin C (Vit C) directly to the eye. We have investigated the stability of antioxidants in aqueous solution and assessed ex-vivo the diffusion of GSH through two ocular membranes, namely cornea and sclera, either in solution or included in a semisolid insert. We have also carried out the hen’s egg-chlorioallantoic membrane test (HET-CAM) to evaluate the ocular irritancy of the different antioxidant solutions. Our results showed that GSH is stable for up to 30 days at 4 °C in darkness and it is not an irritant to the eye. The diffusion studies revealed that the manufactured formulation, a semisolid insert containing GSH, could deliver this tripeptide directly to the eye in a sustained manner. MDPI 2020-09-10 /pmc/articles/PMC7558315/ /pubmed/32927681 http://dx.doi.org/10.3390/pharmaceutics12090861 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sebastián-Morelló, María
Alambiaga-Caravaca, Adrián M.
Calatayud-Pascual, María Aracely
Rodilla, Vicent
Balaguer-Fernández, Cristina
Miranda, María
López-Castellano, Alicia
Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases
title Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases
title_full Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases
title_fullStr Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases
title_full_unstemmed Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases
title_short Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases
title_sort ex-vivo trans-corneal and trans-scleral diffusion studies with ocular formulations of glutathione as an antioxidant treatment for ocular diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558315/
https://www.ncbi.nlm.nih.gov/pubmed/32927681
http://dx.doi.org/10.3390/pharmaceutics12090861
work_keys_str_mv AT sebastianmorellomaria exvivotranscornealandtransscleraldiffusionstudieswithocularformulationsofglutathioneasanantioxidanttreatmentforoculardiseases
AT alambiagacaravacaadrianm exvivotranscornealandtransscleraldiffusionstudieswithocularformulationsofglutathioneasanantioxidanttreatmentforoculardiseases
AT calatayudpascualmariaaracely exvivotranscornealandtransscleraldiffusionstudieswithocularformulationsofglutathioneasanantioxidanttreatmentforoculardiseases
AT rodillavicent exvivotranscornealandtransscleraldiffusionstudieswithocularformulationsofglutathioneasanantioxidanttreatmentforoculardiseases
AT balaguerfernandezcristina exvivotranscornealandtransscleraldiffusionstudieswithocularformulationsofglutathioneasanantioxidanttreatmentforoculardiseases
AT mirandamaria exvivotranscornealandtransscleraldiffusionstudieswithocularformulationsofglutathioneasanantioxidanttreatmentforoculardiseases
AT lopezcastellanoalicia exvivotranscornealandtransscleraldiffusionstudieswithocularformulationsofglutathioneasanantioxidanttreatmentforoculardiseases